Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0HMQLM)
| ADC Name |
KHN922
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
KHN922
Click to Show/Hide
|
|||||
| Organization |
Kanghong Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
7.5 (3.9+3.6)
|
|||||
| Antibody Name |
Patritumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
Exatecan+Triptolide
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)+RNA polymerase II
|
Target Info | ||||
| Linker Name |
Mc-PEG2-VA-PAB+DBCO-PEG4-GGFG
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines+glycoside
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC